Ibrolipim

Ibrolipim (NO-1886) is an orally active lipoprotein lipase (LPL) -promoting agent. Ibrolipim decreases plasma triglycerides, increases high-density lipoprotein cholesterol levels. Ibrolipim has renoprotective and hypolipidemic effects[1][2][3].

Product Specifications

CAS Number

[133208-93-2]

Product Name Alternative

NO-1886

UNSPSC

12352005

Hazard Statement

H301

Target

Lipase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ibrolipim.html

Purity

99.48

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

BrC1=CC(C#N)=C(C=C1)NC(C2=CC=C(C=C2)CP(OCC)(OCC)=O)=O

Molecular Formula

C19H20BrN2O4P

Molecular Weight

451.25

Precautions

H301

References & Citations

[1]Chen SG, et al. Ibrolipim increases ABCA1/G1 expression by the LXRα signaling pathway in THP-1 macrophage-derived foam cells. Acta Pharmacol Sin. 2010 Oct;31 (10) :1343-9.|[2]Kano S, et al. NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats. Metabolism. 2006 Feb;55 (2) :151-8.|[3]Liu Y, et al. Preventive effect of Ibrolipim on suppressing lipid accumulation and increasing lipoprotein lipase in the kidneys of diet-induced diabetic minipigs. Lipids Health Dis. 2011 Jul 16;10:117.